Which has stronger earnings and valuation, AMPE or HEPA?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is AMPE or HEPA more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Hepion Pharmaceuticals N/A -812.56% -207.31%

Do analysts recommend AMPE or IMCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AMPE or IMCC more profitable?

Ampio Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A IM Cannabis -39.62% N/A -58.32%

Which has preferable valuation & earnings, BPTSY or AMPE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is BPTSY or AMPE more profitable?

Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Ampio Pharmaceuticals N/A N/A N/A

Is AMPE or SRNE more profitable?

Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Sorrento Therapeutics N/A N/A N/A

Do analysts recommend AMPE or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Ampio Pharmaceuticals (AMPE) Competitors

$0.18 0.00 (0.00%)

As of 10/1/2026

Compare

AMPE vs. HEPA, IMCC, BPTSY, SRNE, and PRPH

Should you buy Ampio Pharmaceuticals stock or one of its competitors? Ampio Pharmaceuticals's main competitors and comparable companies include Hepion Pharmaceuticals (HEPA), IM Cannabis (IMCC), Biophytis (BPTSY), Sorrento Therapeutics (SRNE), and ProPhase Labs (PRPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Ampio Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

In the previous week, Hepion Pharmaceuticals had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for Hepion Pharmaceuticals and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Hepion Pharmaceuticals	Neutral

Summary

Ampio Pharmaceuticals beats Hepion Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to IM Cannabis?

Ampio Pharmaceuticals (NYSE:AMPE) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Ampio Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
IM Cannabis	-39.62%	N/A	-58.32%

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.22, meaning that its stock price is 122% more volatile than the broader market.

IM Cannabis has higher revenue and earnings than Ampio Pharmaceuticals. IM Cannabis is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
IM Cannabis	$39.17M	0.01	-$8.10M	-$60.66	N/A

In the previous week, IM Cannabis had 3 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Ampio Pharmaceuticals. IM Cannabis' average media sentiment score of 0.25 beat Ampio Pharmaceuticals' score of 0.00 indicating that IM Cannabis is being referred to more favorably in the news media.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
IM Cannabis	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

IM Cannabis beats Ampio Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Biophytis?

Biophytis (NASDAQ:BPTSY) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Ampio Pharmaceuticals	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Ampio Pharmaceuticals	Neutral

0.1% of Biophytis shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ampio Pharmaceuticals beats Biophytis on 3 of the 4 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Sorrento Therapeutics?

Ampio Pharmaceuticals (NYSE:AMPE) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.11, indicating that its share price is 89% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Sorrento Therapeutics	N/A	N/A	N/A

Ampio Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.17	N/A

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Sorrento Therapeutics	Neutral

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ampio Pharmaceuticals beats Sorrento Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to ProPhase Labs?

Ampio Pharmaceuticals (NYSE:AMPE) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Ampio Pharmaceuticals has a beta of 5.96, meaning that its share price is 496% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

Ampio Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Ampio Pharmaceuticals' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
ProPhase Labs	-825.01%	-482.05%	-88.90%

Ampio Pharmaceuticals has higher earnings, but lower revenue than ProPhase Labs. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
ProPhase Labs	$5.06M	0.04	-$53.36M	-$2.25	N/A

In the previous week, ProPhase Labs had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Ampio Pharmaceuticals. ProPhase Labs' average media sentiment score of 0.34 beat Ampio Pharmaceuticals' score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
ProPhase Labs	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ProPhase Labs beats Ampio Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPE vs. The Competition

Export

Metric	Ampio Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$208K	$12.40B	$7.22B	$22.64B
Dividend Yield	N/A	2.63%	2.53%	3.74%
P/E Ratio	-0.02	794.58	272.64	27.58
Price / Sales	N/A	751.12	607.49	20.54
Price / Cash	N/A	81.79	77.38	39.56
Price / Book	0.05	10.32	10.88	4.62
Net Income	-$8.63M	$2.84B	$3.50B	$1.08B
7 Day Performance	N/A	-1.88%	-2.03%	-1.52%
1 Month Performance	N/A	-6.43%	-6.43%	-5.48%
1 Year Performance	11.44%	-3.73%	8.95%	5.05%

Ampio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	6
HEPA Hepion Pharmaceuticals	N/A	$0.06 flat	N/A	+117.4%	$720K	N/A	N/A	20	Gap Up High Trading Volume
IMCC IM Cannabis	0.2373 of 5 stars	$3.01 +3.3%	N/A	-96.2%	$622K	$39.17M	N/A	44	High Trading Volume
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30
SRNE Sorrento Therapeutics	N/A	$0.00 +60.0%	N/A	-77.1%	$441K	$60.32M	N/A	949

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AMPE) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. HEPA, IMCC, BPTSY, SRNE, and PRPH

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Summary

How does Ampio Pharmaceuticals compare to IM Cannabis?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Summary

How does Ampio Pharmaceuticals compare to Sorrento Therapeutics?

Summary

How does Ampio Pharmaceuticals compare to ProPhase Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ampio Pharmaceuticals (AMPE) Competitors

AMPE vs. HEPA, IMCC, BPTSY, SRNE, and PRPH

How does Ampio Pharmaceuticals compare to Hepion Pharmaceuticals?

Is AMPE or HEPA more profitable?

Do insiders and institutionals believe in AMPE or HEPA?

Which has more volatility and risk, AMPE or HEPA?

Which has stronger earnings and valuation, AMPE or HEPA?

Does the media prefer AMPE or HEPA?

Summary

How does Ampio Pharmaceuticals compare to IM Cannabis?

Is AMPE or IMCC more profitable?

Do insiders and institutionals have more ownership in AMPE or IMCC?

Which has more volatility and risk, AMPE or IMCC?

Which has higher valuation & earnings, AMPE or IMCC?

Does the media favor AMPE or IMCC?

Do analysts recommend AMPE or IMCC?

Summary

How does Ampio Pharmaceuticals compare to Biophytis?

Is BPTSY or AMPE more profitable?

Which has preferable valuation & earnings, BPTSY or AMPE?

Which has more volatility & risk, BPTSY or AMPE?

Does the media refer more to BPTSY or AMPE?

Do insiders and institutionals have more ownership in BPTSY or AMPE?

Summary

How does Ampio Pharmaceuticals compare to Sorrento Therapeutics?

Which has more risk & volatility, AMPE or SRNE?

Is AMPE or SRNE more profitable?

Which has preferable earnings and valuation, AMPE or SRNE?

Does the media prefer AMPE or SRNE?

Do insiders & institutionals believe in AMPE or SRNE?

Summary

How does Ampio Pharmaceuticals compare to ProPhase Labs?

Which has more volatility and risk, AMPE or PRPH?

Is AMPE or PRPH more profitable?

Which has better earnings and valuation, AMPE or PRPH?

Does the media prefer AMPE or PRPH?

Do analysts recommend AMPE or PRPH?

Do institutionals and insiders hold more shares of AMPE or PRPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPE vs. The Competition

Ampio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools